On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
The field of mass spectrometry has come a long way since its inception in the late 1890s by particle physicists. Through continuous innovation over the last century, it has evolved into a unique technology. After the two ionization technologies, ESI and MALDI, were awarded the Nobel Prize in 2002, mass spectrometry moved beyond its traditional role in physical chemistry to become a key technology in the biological sciences.
The complexity of living organisms and the broad scope of modern biology provide ample opportunities for technological innovation in the field of mass spectrometry. Consequently, mass spectrometry is playing an increasingly important role in the discovery of new biological findings, disease biomarkers, and mechanisms of complex diseases.
Our research focuses on developing cutting-edge high-throughput multi-omics technologies, such as single-cell proteomics, absolute quantitative proteomics, glycomics, and more, with the goal of addressing important fundamental biological questions and unmet clinical needs.
By exploring and revealing the unknowns in biomedical and clinical research, we aim to establish standardized procedures for the development and validation of clinical biomarkers, with the aim of contributing to human health.
